Biosimilars Regulatory Framework Market 2016 Latest Report Available Online at Hexa Reports
- Submitted by: HexaReports99
- Views: 58
- Category: Other
- Date Submitted: 05/15/2016 11:56 PM
- Pages: 3
- Report this Essay
Hexa Reports
Market Research Reports and Insightful Company Profiles
Biosimilars Regulatory Framework Market Share,
Size, Trends, Growth, Analysis and Outlook Research
Report by Hexa Reports
The biosimilars market is undergoing rapid change with developments such as the recent approvals of
infliximab and trastuzumab heralding a new era. In order to keep up with the pace of change in the
marketplace, regulatory agencies have been developing updated guidance around the development and
approval of biosimilars, but there is still a lack of consistency, particularly between the two leading
agencies - the FDA and EMA.
Browse Detail Report With TOC @ http://www.hexareports.com/report/biosimilars-biosimilars-onthe-cusp-of-a-new-era/details
Moreover, there are some concerns around biosimilar use, for example with physicians worried about
how similar certain drugs are and whether they can safely be used in particular patient populations such
as transplant, due to the potential for variance in efficacy and tolerability. Despite this, it is expected
that the biosimilar market will continue to experience significant growth in the next five to ten years,
being driven by the extensive pipeline and the number of companies becoming involved in this area including some big pharma who are seizing the opportunity to develop biosimilar versions of competitor
products in order to ensure they are able to compete at all levels.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/89663
Scope
The report covers the following key areas - An overview and background about biosimilars - what they are and a timeline of their development
- Key concerns regarding the development and use of biosimilars
Hexa Reports
Market Research Reports and Insightful Company Profiles
- An overview of the issues around automatic substitution with biosimilars
- The regulatory landscape for biosimilars, including a comparison of FDA and EMA guidelines
- Recent...
Market Research Reports and Insightful Company Profiles
Biosimilars Regulatory Framework Market Share,
Size, Trends, Growth, Analysis and Outlook Research
Report by Hexa Reports
The biosimilars market is undergoing rapid change with developments such as the recent approvals of
infliximab and trastuzumab heralding a new era. In order to keep up with the pace of change in the
marketplace, regulatory agencies have been developing updated guidance around the development and
approval of biosimilars, but there is still a lack of consistency, particularly between the two leading
agencies - the FDA and EMA.
Browse Detail Report With TOC @ http://www.hexareports.com/report/biosimilars-biosimilars-onthe-cusp-of-a-new-era/details
Moreover, there are some concerns around biosimilar use, for example with physicians worried about
how similar certain drugs are and whether they can safely be used in particular patient populations such
as transplant, due to the potential for variance in efficacy and tolerability. Despite this, it is expected
that the biosimilar market will continue to experience significant growth in the next five to ten years,
being driven by the extensive pipeline and the number of companies becoming involved in this area including some big pharma who are seizing the opportunity to develop biosimilar versions of competitor
products in order to ensure they are able to compete at all levels.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/89663
Scope
The report covers the following key areas - An overview and background about biosimilars - what they are and a timeline of their development
- Key concerns regarding the development and use of biosimilars
Hexa Reports
Market Research Reports and Insightful Company Profiles
- An overview of the issues around automatic substitution with biosimilars
- The regulatory landscape for biosimilars, including a comparison of FDA and EMA guidelines
- Recent...